In Section C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. All round, our current work highlights the potential utilization of ARV-825 in combination https://davidf444seo7.hazeronwiki.com/user